FOXM1 and breast cancer: Notably, BIRC5 and FOXM1 expression was also reduced in taxane-treated breast cancer patients (Figure 6), and FOXM1 expression was upregulated in most of the PTXR TNBC cell lines (Figure 5F) consistent with its established role in drug resistance to genotoxic agents, such as taxane and epirubicin [27].